




23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax® 23)



DECISION: Administer PPSV23
 Do NOT administer PPSV23 until review of PCV13 decision is made.
 If PCV13 is given, PPSV23 will need to wait a year. Date to readdress: _____

Do not administer...

- It has not been five years since resident's last vaccine: Date administered: _____ Follow-up date: _____
- Resident was previously vaccinated.
- Vaccine is contraindicated due to medical condition.
- Resident refused.

Reviewer: _____ Date: _____

Download the U.S. Centers for Disease Control's vaccine decision making app at <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html>.

Reference:

[COVID-19 Vaccine FAQs for Healthcare Professionals](#) | CDC accessed 3/18/2021

[PneumoRecs VaxAdvisor: Vaccine Provider App](#) | CDC accessed 3/18/2021

Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., & Pilishvili, T. (2019). "Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices." *MMWR. Morbidity and mortality weekly report*, 68(46), 1069–1075. <https://doi.org/10.15585/mmwr.mm6846a5>